Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Merck Group
Deal Size : $1,400.0 million
Deal Type : Partnership
Caris Partners with Merck KGaA to Discover Novel Cancer Targets and Develop ADCs
Details : The partnership aims to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients, by leveraging Caris' proprietary ADAPT Biotargeting platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Merck Group
Deal Size : $1,400.0 million
Deal Type : Partnership
Details : Under the agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions to enhance Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Incyte Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Incyte will leverage Caris’ data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Incyte Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Details : Caris’ proprietary ADAPT biotargeting system is able to identify many cancer-specific proteins that would elude classical identification methods, increasing the potential to identify truly novel targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 01, 2023
Details : Under the terms of the new agreement, Xencor will receive exclusive worldwide rights to research, develop and commercialize antibody products directed to up to three targets discovered under the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Flare Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular prof...
Product Name : FX-909
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Flare Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership